# Jain Dataset - ELISA-based Fragments (SSOT)
# Source: test_datasets/jain/processed/jain_with_private_elisa_FULL.csv
# Labeling: ELISA flags (0→specific, 1-3→mild, ≥4→non-specific)
# Distribution: 94 specific / 22 non-specific / 21 mild
# Generated: 2025-11-06
# Script: preprocessing/jain/step3_extract_fragments.py
id,sequence,label,elisa_flags,source
abituzumab,QDISNY,0.0,0,jain2017_pnas
abrilumab,QGISSW,0.0,0,jain2017_pnas
adalimumab,QGIRNY,0.0,0,jain2017_pnas
alemtuzumab,QNIDKY,0.0,0,jain2017_pnas
alirocumab,QSVLYRSNNRNF,0.0,0,jain2017_pnas
anifrolumab,QSVSSSF,0.0,0,jain2017_pnas
atezolizumab,QDVSTA,0.0,0,jain2017_pnas
bapineuzumab,QSLLDSDGKTY,0.0,0,jain2017_pnas
basiliximab,SSRSY,0.0,0,jain2017_pnas
bavituximab,QDIGSS,0.0,0,jain2017_pnas
belimumab,SLRSYY,1.0,6,jain2017_pnas
benralizumab,EDIINY,0.0,0,jain2017_pnas
bevacizumab,QDISNY,0.0,0,jain2017_pnas
bimagrumab,SSDVGSYNY,0.0,0,jain2017_pnas
blosozumab,QDVHTA,1.0,6,jain2017_pnas
bococizumab,QGISSA,1.0,6,jain2017_pnas
brentuximab,QSVDFDGDSY,,3,jain2017_pnas
briakinumab,RSNIGSNT,1.0,4,jain2017_pnas
brodalumab,QSVSSN,,1,jain2017_pnas
canakinumab,QSIGSS,0.0,0,jain2017_pnas
carlumab,QSVSDAY,1.0,4,jain2017_pnas
certolizumab,QNVGTN,0.0,0,jain2017_pnas
cetuximab,QSIGTN,0.0,0,jain2017_pnas
cixutumumab,SLRSYY,1.0,6,jain2017_pnas
clazakizumab,QSINNE,0.0,0,jain2017_pnas
codrituzumab,QSLVHSNRNTY,1.0,6,jain2017_pnas
crenezumab,QSLVYSNGDTY,0.0,0,jain2017_pnas
dacetuzumab,QSLVHSNGNTF,0.0,0,jain2017_pnas
daclizumab,SSISY,,1,jain2017_pnas
dalotuzumab,QSIVHSNGNTY,1.0,5,jain2017_pnas
daratumumab,QSVSSY,0.0,0,jain2017_pnas
denosumab,QSVRGRY,1.0,5,jain2017_pnas
dinutuximab,QSLVHRNGNTY,0.0,0,jain2017_pnas
drozitumab,SLRSYY,0.0,0,jain2017_pnas
duligotuzumab,QNIATD,1.0,6,jain2017_pnas
dupilumab,QSLLYSIGYNY,1.0,5,jain2017_pnas
eculizumab,ENIYGA,0.0,0,jain2017_pnas
efalizumab,KTISKY,0.0,0,jain2017_pnas
eldelumab,QSVSSSY,0.0,0,jain2017_pnas
elotuzumab,QDVGIA,0.0,0,jain2017_pnas
emibetuzumab,SSVSSIY,1.0,6,jain2017_pnas
enokizumab,QHVITH,0.0,0,jain2017_pnas
epratuzumab,QSVLYSANHKNY,,1,jain2017_pnas
etrolizumab,ESVDDL,,2,jain2017_pnas
evolocumab,SSDVGGYNS,,2,jain2017_pnas
farletuzumab,SSISSNN,0.0,0,jain2017_pnas
fasinumab,QAIRND,0.0,0,jain2017_pnas
fezakinumab,SSNIGAGYG,0.0,0,jain2017_pnas
ficlatuzumab,ENVVSY,0.0,0,jain2017_pnas
figitumumab,QGIRND,,3,jain2017_pnas
fletikumab,QGISSA,0.0,0,jain2017_pnas
foralumab,QSVSSY,,2,jain2017_pnas
fresolimumab,QSLGSSY,0.0,0,jain2017_pnas
fulranumab,QGISSA,,1,jain2017_pnas
galiximab,TSNIGGYD,0.0,0,jain2017_pnas
ganitumab,QSLLHSNGYNY,0.0,0,jain2017_pnas
gantenerumab,QSVSSSY,1.0,6,jain2017_pnas
gemtuzumab,ESLDNYGIRF,0.0,0,jain2017_pnas
gevokizumab,QDISNY,0.0,0,jain2017_pnas
girentuximab,QNVVSA,0.0,0,jain2017_pnas
glembatumumab,QSVDNN,0.0,0,jain2017_pnas
golimumab,QSVYSY,,1,jain2017_pnas
guselkumab,SSNIGSGYD,,1,jain2017_pnas
ibalizumab,QSLLYSTNQKNY,0.0,0,jain2017_pnas
imgatuzumab,QGINNY,1.0,5,jain2017_pnas
infliximab,QFVGSS,0.0,0,jain2017_pnas
inotuzumab,QSLANSYGNTF,,3,jain2017_pnas
ipilimumab,QSVGSSY,0.0,0,jain2017_pnas
ixekizumab,RSLVHSRGNTY,1.0,6,jain2017_pnas
lampalizumab,TDIDDD,0.0,0,jain2017_pnas
lebrikizumab,KSVDSYGNSF,0.0,0,jain2017_pnas
lenzilumab,QSVGTN,1.0,6,jain2017_pnas
lintuzumab,ESVDNYGISF,0.0,0,jain2017_pnas
lirilumab,QSVSSY,0.0,0,jain2017_pnas
lumiliximab,QDIRYY,0.0,0,jain2017_pnas
matuzumab,SSVTY,0.0,0,jain2017_pnas
mavrilimumab,GSNIGAPYD,0.0,0,jain2017_pnas
mepolizumab,QSLLNSGNQKNY,0.0,0,jain2017_pnas
mogamulizumab,RNIVHINGDTY,0.0,0,jain2017_pnas
motavizumab,SRVGY,,1,jain2017_pnas
muromonab,SSVSY,0.0,0,jain2017_pnas
natalizumab,QDINKY,0.0,0,jain2017_pnas
necitumumab,QSVSSY,0.0,0,jain2017_pnas
nimotuzumab,QNIVHSNGNTY,0.0,0,jain2017_pnas
nivolumab,QSVSSY,0.0,0,jain2017_pnas
obinutuzumab,KSLLHSNGITY,0.0,0,jain2017_pnas
ocrelizumab,SSVSY,0.0,0,jain2017_pnas
ofatumumab,QSVSSY,0.0,0,jain2017_pnas
olaratumab,QSVSSY,0.0,0,jain2017_pnas
olokizumab,QDIGIS,0.0,0,jain2017_pnas
omalizumab,QSVDYDGDSY,0.0,0,jain2017_pnas
onartuzumab,QSLLYTSSQKNY,0.0,0,jain2017_pnas
otelixizumab,SGNIENNY,0.0,0,jain2017_pnas
otlertuzumab,ENVYSY,0.0,0,jain2017_pnas
ozanezumab,KSLLYKDGKTY,,3,jain2017_pnas
palivizumab,LSVGY,0.0,0,jain2017_pnas
panitumumab,QDISNY,0.0,0,jain2017_pnas
panobacumab,QSLVYSDGNTY,0.0,0,jain2017_pnas
parsatuzumab,QSLVHINAITY,1.0,6,jain2017_pnas
patritumab,QSVLYSSSNRNY,1.0,4,jain2017_pnas
pembrolizumab,KGVSTSGYSY,0.0,0,jain2017_pnas
pertuzumab,QDVSIG,0.0,0,jain2017_pnas
pinatuzumab,QSIVHSVGNTF,0.0,0,jain2017_pnas
polatuzumab,QSVDYEGDSF,0.0,0,jain2017_pnas
ponezumab,QSLLYSDAKTY,1.0,4,jain2017_pnas
radretumab,QSVSSSF,0.0,0,jain2017_pnas
ramucirumab,QGIDNW,0.0,0,jain2017_pnas
ranibizumab,QDISNY,,1,jain2017_pnas
reslizumab,EGISSY,0.0,0,jain2017_pnas
rilotumumab,QSVDSN,0.0,0,jain2017_pnas
rituximab,SSVSY,0.0,0,jain2017_pnas
robatumumab,QSIGSS,1.0,4,jain2017_pnas
romosozumab,QDISNY,0.0,0,jain2017_pnas
sarilumab,QGISSW,0.0,0,jain2017_pnas
secukinumab,QSVSSSY,0.0,0,jain2017_pnas
seribantumab,SSDVGSYNV,0.0,0,jain2017_pnas
sifalimumab,QSVSSTY,,3,jain2017_pnas
siltuximab,SSVSY,0.0,0,jain2017_pnas
simtuzumab,KSLLHSNGNTY,1.0,6,jain2017_pnas
sirukumab,ISVSY,1.0,5,jain2017_pnas
tabalumab,QSVSRY,0.0,0,jain2017_pnas
tanezumab,QSISNN,,1,jain2017_pnas
teplizumab,SSVSY,,2,jain2017_pnas
tigatuzumab,QDVGTA,0.0,0,jain2017_pnas
tildrakizumab,ENIYSY,0.0,0,jain2017_pnas
tocilizumab,QDISSY,0.0,0,jain2017_pnas
tovetumab,QSFSRY,0.0,0,jain2017_pnas
tralokinumab,IIGSKL,0.0,0,jain2017_pnas
trastuzumab,QDVNTA,0.0,0,jain2017_pnas
tremelimumab,QSINSY,0.0,0,jain2017_pnas
urelumab,QSVSSY,0.0,0,jain2017_pnas
ustekinumab,QGISSW,,3,jain2017_pnas
vedolizumab,QSLAKSYGNTY,0.0,0,jain2017_pnas
veltuzumab,SSVSY,0.0,0,jain2017_pnas
visilizumab,SSVSY,,3,jain2017_pnas
zalutumumab,QDISSA,,1,jain2017_pnas
zanolimumab,QDISSW,0.0,0,jain2017_pnas
